Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer

Treatment with the investigational next-generation KRAS-G12C inhibitor elisrasib led to clinical benefit in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12C mutation and whose disease progressed after prior therapies, according to results presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.